Clinical Drug Research - Brain Research Unit 

Merja Hallikainen
Clinical Research Director

University of Eastern Finland
School of Medicine
Institute of Clinical Medicine - Neurology
Brain Research Unit

Yliopistonranta 1B
70210 Kuopio
Finland

+358 40 567 84 33
merja.hallikainen (at) uef.fi 

Major Research and Clinical Interests 

  • Alzheimer's disease
  • Memory disorders

Employment and Experience

  • Rehabilitation Center of Siilinjärvi, Physician 1984-1987
  • Department of Neurology, Neurosurgery and Neurophysiology, Resident 1987-1989
  • Posio Health Center, Physician 1989-1990
  • Department of Neurology, Resident 1991-1996
  • Department of Neurology, Neurologist 1996-2002
  • Clinical Research Director, Brain Research Unit, UEF 2002 -

Academic Degrees

  • MD, Medical Faculty, Kuopio University 1984
  • Board Certified Doctor, Medical Board, Helsinki 1985
  • Board Certified Specialist in Neurology, Medical Board,Helsinki 1996
  • PhD, Kuopio University 1996

Selected Publications 

Cortical thickness analysis to detect progressive mild cognitive impairment: a reference to Alzheimer's disease. Julkunen V, Niskanen E, Muehlboeck S, Pihlajamäki M, Könönen M, Hallikainen M, Kivipelto M, Tervo S, Vanninen R, Evans A, Soininen H. Dement Geriatr Cogn Disord 2009:28:404-412.

Olfactory identification in non-demented elderly population and mild cognitive impairment: a comparison of performance in clinical odor identification versus Boston Naming Test. Laakso MP, Tervo S, Hänninen T, Vanhanen M, Hallikainen M, Soininen H. J Neural Transm 2009:116:891-895.

PET amyloid ligand (11C)PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka S-K, Jauhiainen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H. Dement Geriatr Cogn Disord 2008:26:378-383.

A multi-metabolite analysis of serum by 1H NMR spectroscopy: Early systemic signs of Alzheimer's disease. Tukiainen T, Tynkkynen T, Mäkinen V-P, Jylänki P, Kangas A, Hokkanen J, Vehtari A, Gröhn O, Hallikainen M, Soininen H, Kivipelto M, Groop P-H, Kaski K, Laatikainen R, Soininen P, Pirttilä T, Ala-Korpela M, Soininen H.Biochem Biophys Res Commun 2008:375:356-361.

Apolipoprotein E epsilon4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. Hämäläinen A, Grau-Olivares M, Tervo S, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hänninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala E-L, Nissinen A, Vanninen RL, Soininen H. Neurodegenerative Dis 2008:5:186-189.

MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hänninen T, Pihlajamäki M, Laakso MP, Hallikainen M, Hämäläinen A, Vanhanen M, Helkala E-L, Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H, Pennanen C. Neurobiol Aging 2008:29:31-38.

Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Hämäläinen A, Tervo S, Grau-Olivares M, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hänninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala E-L, Nissinen A, Vanninen R, Soininen H. Neuroimage 2007:37:1122-1131.

CSF Abeta42, tau and phosphorylated tau, APOE epsilon4 allele and MCI type in progressive MCI. Herukka S-K, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T. Neurobiol Aging 2007:28:507-514.

Cerebrospinal fluid Abeta42, tau and phosphorylated tau predict progression in patients with cognitive impairment. Herukka S-K, Hallikainen M, Tervo S, Helisalmi S, Tapiola T, Soininen H, Pirttilä T. In: Vellas B, Winblad B, Grundman M, Fitten LJ, Feldman H, Giacobini E, Kurz A, eds. Research and Practice in Alzheimer´s Disease, p. 245-250. Paris: Serdi, 2006. Vol. 11.